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ABSTRACT  
 
New drugs are highly needed to control mycobacterial infections. This study aimed at screening 
ethnobotanically selected plants extracted using organic solvents for their antimycobacterial activity. In vitro 
assays were performed on Mycobacterium smegmatis, Mycobacterium avium, Mycobacterium bovis Bacille 
Calmette Guerin (BCG), Mycobacterium tuberculosis and Mycobacterium ulcerans using the Resazurin 
Microtiter Assay. Cytotoxicity was assessed on Human lung fibroblast cells (MRC5) and bone marrow-derived 
macrophages (BMDM) using the MTS tetrazolium assay. The most promising extract from Annickia 
chlorantha stem bark (ACsbI) was tested for intracellular antimycobacterial activity against M. smegmatis 
using infected BMDM. Sixty crude extracts, 19 fractions, and 2 purified compounds were obtained from 19 
Cameroonian medicinal plants. Results showed that crude extracts mainly inhibited BCG, while interface 
fractions from A. chlorantha stem bark (ACsbI) and stem (ACstI) displayed the strongest activity against M. 
ulcerans, with Minimal Inhibitory Concentrations (MIC) of 1.95 and 7.81 µg/ml respectively. Two compounds 
purified from Sorindeia juglandifolia fruits (SJfr 3.6 and SJfr 4.5) showed activity against BCG and M. 
ulcerans at 3.9 µg/ml and 62.5 µg/ml respectively. Finally, ACsbI showed no toxicity against MRC5 cells and 
BMDM and inhibited the growth of intracellular M. smegmatis. The results achieved in this investigation 
support the traditional to use of these plants and the need to investigate them in deeper details to be able to find 
alternatives for the existing antimycobacterial drugs.  
© 2014 International Formulae Group. All rights reserved. 
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INTRODUCTION 
Mycobacteria constitute a very 
heterogeneous genus, comprising highly 
pathogenic as well as opportunistic or 
nonpathogenic species. Amongst the 
pathogenic species, Mycobacterium 
V. F. DONKENG DONFACK et al. / Int. J. Biol. Chem. Sci. 8(1): 273-288, 2014 
 
 
 
274 
tuberculosis, the causative agent of 
tuberculosis (TB), is the leading one, 
responsible for an estimated one-third of the 
world’s human population infection (WHO, 
2004; TB Alliance, 2011). Buruli ulcer (BU), 
caused by Mycobacterium ulcerans, is 
globally the third most frequent mycobacterial 
disease after TB and leprosy (Asiedu et al., 
2000; WHO, 2011). However, in some 
countries, as Benin and Côte d’Ivoire, the 
number of cases may exceed those of TB and 
leprosy (Asiedu et al., 2000). On the other 
hand, opportunistic or nonpathogenic 
mycobacteria such as Mycobacterium avium 
and Mycobacterium smegmatis can cause 
disease in imunocompromised people such as 
AIDS patients (Daley and Griffith, 2010; 
Sexton and Harrison, 2008; Cangelosi et al., 
2001). Infections with these species are very 
hard to treat, requiring multi-drug therapy for 
prolonged periods (WHO, 2004; TB Alliance, 
2011). Furthermore, drug-resistant strains 
render the treatment even more difficult, 
highlighting the need for a drug discovery 
pipeline to ensure the availability of new 
chemical entities with improved mechanisms 
of antimycobacterial action. 
A large proportion of the world 
population relies on traditional medicine for 
their primary healthcare, due to cultural 
believes or lack of alternatives (WHO 2004; 
Hannan et al., 2011; Anon, 2002). Within this 
framework, plant products have proven 
interesting antimicrobial potency (Okunade et 
al., 2004, Vikrant, 2011). In Cameroon, there 
is a rich tradition of using herbal medicine for 
the treatment of various mycobacterial 
infections (Adjanohoun et al., 1996; Kimbi et 
al., 1996; Focho et al., 2010). 
This paper reports the 
antimycobacterial activity of 60 crude 
extracts, 19 fractions, and 2 purified 
compounds from 19 Cameroonian medicinal 
plants selected based on their traditional uses 
against infectious diseases in general and 
particularly TB and related diseases.  
 
MATERIALS AND METHODS  
Collection of plant materials 
Nineteen plants were selected based on 
their ethnobotanical use for the treatment of 
various ailments including cough, bronchitis, 
chest complaints, pneumonia, TB and other 
related diseases (Nishiyama et al., 2004; 
Ibekwe and Orok, 2010). The plants were 
subsequently collected between December 
2009 and October 2010 at Mt Kalla (Yaoundé 
area-Centre region), Lolodorf (South region of 
Cameroon), and Dschang (West region). The 
ethnobotanical survey was conducted in strict 
respect of the current regulations of 
biodiversity protection and rural population’s 
customary rights. In the preliminary step of 
the survey, legal authorities (villages’ heads) 
from each study site were contacted to seek 
authorization to investigate within their 
communities. During a face-to-face 
interaction, the purpose and the procedure of 
the work, as well as the expected benefits and 
rights were explained to villages’ heads. The 
traditional herbal practitioners willing to 
participate on the study (or their interpreters) 
had signed the informed consent form before 
further interactions. The data were collected 
following a questionnaire prepared for the 
study by Dr. Nole Tsabang, an ethnobotanist 
at the Institute for Medical Research and 
Medicinal Plants Study, Yaoundé, Cameroon. 
Voucher specimens of each plant were dried 
and deposited at the Cameroon National 
Herbarium, Yaoundé. The information on 
plant materials is summarized in Table 1 
where plants are listed with their traditional 
uses, voucher specimen’s reference numbers, 
the solvent and yields of extraction. 
 
Plant extraction 
Air-dried (at room temperature) and 
ground (using a blender) plant materials were 
extracted by maceration using appropriate 
solvents. Annonaceae plants samples were 
extracted according to the method previously 
described by Alali et al. (1999). This method 
was chosen because it is designed to isolate 
acetogenins (or rich fractions) that were 
shown to exert high potency against bacteria 
(Vairappan and Tan, 2009; Alali et al., 1999). 
Plant powders (500 g) were individually 
macerated in 95% ethanol for 72 h. The dried 
ethanolic extracts obtained were further 
partitioned between water (H2O) and 
methylene chloride (CH2Cl2) (1:1, v/v). The 
CH2Cl2 residues were partitioned between 
hexane and 90% methanol (1:1, v/v). The 
different fractions were evaporated to dry 
under reduced pressure using a Büchi R111 
Rotavapor. The water layers were evaporated 
under ventilation at room temperature. In 
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addition, interface precipitates were obtained 
during residues partition between 
CH2Cl2/H2O. 
Samples of non Annonaceae plants that 
do not contain acetogenins were extracted by 
repeated maceration in methanol. These 
included Aframomum melegueta, 
Chlorophytum macrophyllum, Solanum 
aculeastrum, Spilanthes filicaulis and 
Sorindeia juglandifolia. 
Following a Label extension strategy 
(Nwaka and Hudson, 2006), methanolic crude 
extract, fractions (SJfr 1.1, SJfr 2.1, SJfr 2.2, 
SJfr 2.3, SJfr 3.1, SJfr 3.2, SJfr 3.3, SJfr 3.41, 
SJfr 3.42, SJfr 3.5, SJfr 4.1, SJfr 4.2, SJfr 4.3, 
SJfr 4.4), and compounds [2,3,6-trihydroxy 
benzoic acid (SJfr 3.6) (formula 1) and 2,3,6-
trihydroxy methyl benzoate (SJfr 4.5) 
(formula 2)] from the fruit of S. juglandifolia  
that were previously prepared in our 
laboratory and that showed good potency 
against infectious pathogens (Kamkumo et al., 
2012) were also screened for 
antimycobacterial activity. 
 
Evaluation of the biological activities 
Preparation of stock solutions  
Stock solutions (100 mg/ml for plants 
crude extracts and 2 mg/ml for fractions and 
purified compounds) were prepared by 
dissolving each extract in 2% DMSO/distilled 
water, and filtrating through a 0.22 µm 
syringe filter. For the intracellular 
antimycobacterial activity and cytotoxicity 
assays, stock solutions were prepared using 
2% DMSO in complete Dulbecco’s modified 
Eagle’s medium [cDMEM, consisting of 
Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco) with 10 mM HEPES            
(Gibco), 1 mM sodium pyruvate (Gibco), 2 
mM L-glutamine (Gibco), 10% heat-
inactivated fetal bovine serum (Sigma 
Aldrich)], filtrated through a 0.22 µm syringe 
filter. The stock solutions were serially diluted 
either in Middlebrook 7H9 medium 
supplemented with ADC (Albumin, Dextrose, 
Catalase) or in cDMEM for specific 
experiments. Positive controls were prepared 
at 1 mg/ml for ethambutol (EMB) and 
streptomycin (SM) in distilled water and 
sterilized through a 0.22 µm syringe filter. 
Bacterial strains and growth conditions 
The following mycobacterial strains 
were used in the experiments: M. smegmatis 
strain mc2155 from the American Type 
Culture Collection (ATCC 70008); M. avium 
strain 2447 smT (smooth-transparent) isolated 
from an AIDS patient and obtained from Dr. 
F. Portaels (Institute of Tropical Medicine, 
Antwerp, Belgium); M. ulcerans strain 1615 
obtained from the University of Tennessee, 
USA; BCG Pasteur and M. tuberculosis H37 
Rv, obtained from the Trudeau Institute, USA. 
Mycobacteria were grown at 37 °C on 
solid Middlebrook 7H10 (M. smegmatis and 
M. avium) or Middlebrook 7H11 medium 
(BCG and M. tuberculosis) all supplemented 
with OADC (Oleic-Acid-Albumin-Dextrose-
Catalase) and 0.5% glycerol. M. ulcerans was 
grown at 32 °C on Middlebrook 7H9 agar 
medium enriched with OADC. 
To prepare the inocula, M. smegmatis, 
M. avium, BCG, and M. tuberculosis were 
freshly subcultured in Middlebrook 7H9 
medium containing 0.05% Tween 80 and 
ADC at 37 °C. M. ulcerans was subcultured 
on solid Middlebrook 7H9 medium containing 
OADC enrichment for 6 weeks at 32 °C. The 
mycobacterial strains were used at their 
exponential growth phase, evaluated by their 
individual growth curve. 
Inocula of bacteria used for in vitro 
experiments, were prepared as described by 
Singh et al. (2012) and Yemoa et al. (2011) 
with few modifications. Briefly, inocula of M. 
smegmatis, BCG, M. ulcerans, M. avium, and 
M. tuberculosis were prepared following the 
McFarland standards, and concentration of 
viable bacteria was obtained by enumerating 
colony forming unit (CFU) per ml on solid 
medium. The concentration of bacteria used in 
the experiments was approximately: 105 
CFU/ml for M. smegmatis, BCG, and M. 
tuberculosis; 106 CFU/ml for M. ulcerans, 
and 108 CFU/ml for M. avium. Prior to 
antimycobacterial assay, the absence of 
contamination was confirmed by culturing in 
the Brain and Heart Infusion (BHI) medium 
agar and using Ziehl-Neelsen staining. 
Assessment of in vitro antimycobacterial 
activity of plant extracts 
The antimycobacterial activity was 
assessed in 96 wells microtiter plates 
(Corning, Spain) using the Resazurin 
Microtiter Assay (REMA) as described by 
Singh et al. (2012). Fixed concentration of 
12.5 mg /ml for 60 crude extracts, 0.25 mg 
/ml for 19 fractions and 2 compounds were 
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added to wells containing 100 µl of bacterial 
inocula and incubated at 37 °C for 1 day for 
M. smegmatis, 5 days for M. avium and BCG, 
and 7 days for M. tuberculosis. M. ulcerans 
was incubated for 15 days at 32 °C. Positive 
controls consisted of EMB at 1.875 µg/ml, 
0.166 mg/ml and 3 µg/ml for M. smegmatis, 
M. avium and BCG, respectively, and of SM 
at 2 µg/ml, 18 µg/ml and 4 µg/ml respectively 
for M. ulcerans, M. avium and M. 
tuberculosis. Negative control wells contained 
no drugs and blank contained no inoculum 
and/or drug. Upon incubation periods, 30 µl 
of 0.01% resazurin (Acros Organic NV) were 
added to individual wells and the plates re-
incubated for additional 1 to 3 days and 
checked daily for color change. Change in 
resazurin color from blue to pink indicated 
reduction of the indicator and thus bacterial 
growth.  
The Minimal Inhibitory Concentrations 
(MIC) of inhibitors was assessed using the 
same approach. Briefly, twofold serially 
diluted selected extracts were incubated in the 
range of 12,500 - 97 µg/ml for crude extracts 
and 250 - 1.95 µg/ml for fractions and 
purified compounds with inocula in 96 wells 
microtiter plate (Corning, Spain). EMB and 
SM were used as positive controls. The MIC 
was defined as the lowest drug concentration 
that prevented visible growth of bacteria 
displayed by no color change. 
Minimal Bactericidal Concentrations 
(MBC) of promising plant extracts was 
assessed by sub-culturing MIC test plates on 
solid nutrient Middlebrook 7H9, 7H10, and 
7H11. The MBC was considered as the 
minimal concentration of plant extract needed 
to kill most (≥99.9%) of the initial inoculum 
after incubation for a fixed length of time 
under a given set of conditions (NCCLS, 
1999). All the experiments were done in 
duplicate and repeated 3 times. Fractions 
exhibiting antimycobacterial activity with 
MIC ≤ 7.81 µg/ml against at least 1 
mycobacterial species (ACstI, ACsbI, and SJfr 
3.6) were selected and assessed for 
cytotoxicity against MRC5 cells. 
Assessment of the cytotoxicity of promising 
plants extracts and fractions 
Plant extracts showing 
antimycobacterial activity were assessed for 
cell cytotoxicity against MRC5 cells. 
Subsequently, the cytotoxicity profile of 1 
fraction (ACsbI) that showed no toxic effects 
on MRC5 cells was assessed on BMDM 
prepared from mice (C57BL/6 Ly5.1) as 
described by Oliveira et al. (2005). The 
cytotoxic effect of selected plant extracts was 
evaluated by MTS assay ([3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium] 
(Promega, USA) after 48 h of incubation. 
Detection of cell viability was based on the 
reduction of the tetrazolium salt MTS to 
water-soluble formazan dye by metabolically 
active cells. Briefly, 100 µl of MRC5 cells or 
BMDM were cultured in 96-well plates at 1 × 
105 cells/ml, 24 h before adding 100 µl of 
extract at 0, 125, 250, and 500 µg/ml final 
concentration and incubated for 48 h at 37 °C 
in a 5% CO2 humidified atmosphere. Upon the 
incubation period, the medium was replaced 
with the same volume of cDMEM. MTS 
reagent was added to each well and incubated 
for 2 h at 37 °C. Untreated cells were used as 
negative control. The absorbance was 
recorded at 490 nm using an ELISA plate 
reader (BioteK EL800, USA). The readout 
was directly proportional to the number of 
viable cells in culture (Promega, 2011). 
Percent inhibition of MRC5 cells was 
calculated using optical density. The value of 
cell cytotoxicity at 50% (IC50) in the MTS 
assay was defined as the concentration of test 
extract resulting in a 50% reduction of 
absorbance compared with untreated cells and 
obtained using Graph Pad Prism 5.0. 
Assessment of the intracellular 
antimycobacterial activity of A. chlorantha 
stemback ACsbI fraction 
To assess the intracellular activity of 
ACsbI that exerted no significant cytotoxicity 
on BMDM and MRC5 cells, BMDM were 
cultured in 96-well plates at 1 × 105 cells/ml 
for 24h and the culture medium replaced with 
100 µl of M. smegmatis inoculum containing 
5x105 CFU. Upon a 4 h phagocytosis period  
at 37 °C under 5% CO2 (Rastogi et al., 1987), 
free bacteria were washed out and 100 µl of 
ACsbI at MIC value (250 µg/ml in cDMEM, 
20% LCCM, 2% DMSO) added and incubated 
at 37 oC under 5% CO2 for 24 and 48 h 
(Rastogi et al., 1987 ; Sharbati-Tehrani et al., 
2005). The infected BMDM were lysed 
adding 5 µl of saponin (10%), diluted and 
plated on the Middlebrook 7H10 medium for 
3 days at 37 °C, and the CFU thereafter 
V. F. DONKENG DONFACK et al. / Int. J. Biol. Chem. Sci. 8(1): 273-288, 2014 
 
 
 
277 
enumerated. The experiment was done in 
triplicate and the results expressed as log10 
CFU. 
 
Statistical analysis 
Results are expressed as Means ± SD. 
The comparison between control and treated 
samples was assessed by one-way ANOVA. 
The intracellular activity was evaluated by 
two-way ANOVA using the GraphPad Prism 
5.0 software. Statistically significant 
differences were considered for P values < 
0.05. 
 
RESULTS  
The 19 plants resulting from the 
ethnobotanical survey are listed in Table 1, 
with indication of their traditional uses, plant 
parts studied, extracts, fraction and yields 
obtained (60 crude extracts, 19 fractions, and 
2 purified compounds were obtained with 
yields ranging from 0.019 to 25.44%) 
calculated in percentage (w/w) relative to the 
starting plant material. 
The extracts were initially screened 
against M. smegmatis, M avium, BCG, M. 
ulcerans, and M. tuberculosis at unique 
concentrations of 12,500 µg/ml for crude 
extracts and 250 µg/ml for fractions and 
compounds. From the results obtained, 22 
extracts and fractions and 2 purified 
compounds (Table 2) deriving from 10 plants 
species (Aframomum melegueta, Spilanthes 
filicaulis, Chlorophytum macrophyllum, 
Polyalthia suaveolens, Sorindeia 
juglandifolia, Annickia chlorantha, 
Anonidium mannii, Uvaria baumannii, 
Xylopia africana and Polyalthia oliveri) 
exhibited inhibitory actions, and were 
therefore selected for the MIC and MBC  
determination.  
From the assessment of the selected 
extracts, MIC and MBC were determined as 
presented in Table 2. Crude extracts mainly 
acted on BCG, the most potent being 
UBtwMeOH (MIC= 1,562 µg/ml; MBC= 
3,125 µg/ml), XArH2O (MIC= 3,125 µg/ml; 
MBC= 3,125 µg/ml); CMr (MIC= 3,125 
µg/ml; MBC= 6,250 µg/ml), and 
AMntwMeOH (MIC= 3,125 µg/ml; MBC= 
6,250 µg/ml). The remaining extracts 
presented MIC/MBC values equal or superior 
to 6,250 µg/ml. PSsbMeOH and XArH2O 
showed the broadest range of action. On the 
other hand, M. ulcerans appeared to be highly 
susceptible to the methanolic crude extract of 
P. suaveolens (PSsbMeOH), with MIC and 
MBC values equal to 3,125 µg/ml.  
Concerning the susceptibility of 
mycobacteria to fractions, A. chlorantha stem 
bark and stem interfaces displayed the 
strongest activity against M. ulcerans, with 
low MIC and MBC values at 1.95 and 62.5 
µg/ml respectively for ACsbI, and 7.81 and 
7.81 µg/ml for ACstI. The other promising 
fractions acted at concentrations equal or 
higher than  31.25 µg/ml, and mainly against 
BCG.  
The 2 compounds purified from the 
fruits of S. juglandifolia (SJfr 3.6= 2,3,6-
trihydroxy benzoic acid and SJfr 4.5= 2,3,6-
trihydroxy methyl benzoate) showed 
antimycobacterial activity against BCG and 
M. ulcerans with respective MIC values of 3.9 
µg/ml and 62.5 µg/ml. 
From the MTS cytotoxicity assays 
using MRC5 cells, ACsbI proved to be safe at 
the highest concentration tested (IC50 > 500 
µg/ml). The 2 other fractions, ACstI and SJfr 
3.6, showed cytotoxicity against MRC5 
(Table 3) with IC50 values of 50.82 µg/ml and 
139.4 µg/ml respectively. 
As shown in Table 3, only 1 extract 
from A. chlorantha (ACsbI) was found to be 
safe at 2 fold the MIC value (activity against 
M. smegmatis) and was therefore assessed 
against BMDM. ACsbI was also tested for 
cytotoxicity against BMDM (Figure 1) and 
showed no cytotoxic effects at MIC value and 
was considered for intracellular activity 
assessment. 
For the intracellular antimycobacterial 
activity, BMDM infected with M. smegmatis 
were treated with the extract (ACsbI) and the 
result evaluated after 0, 24 and 48 h post-
infection as showed in Figure 2. 
As shown in Figure 2, the bacterial load 
in untreated macrophages nearly doubled 
within 48 h, while it slightly decreased or 
remained constant for BMDM treated with 
ACsbI. The time-kill kinetic showed that the 
activity of ACsbI is almost constant 
throughout the 48 h of exposition. This result 
suggests that drugs inhibited the intracellular 
mycobacterial growth. 
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(1) SJfr 3.6: 2,3,6-trihydroxybenzoic acid
Yield: 0.062%; m/z= 170; mp= 188.5-190; 
yellow crystals
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(2) SJfr 4.5: 2,3,6-trihydroxymethyl benzoate. 
Yield: 0.0017%; m/z= 184; mp= 139-140.5; pale 
yellow crystals
 
 
The synthesis of these compounds was previously described by Kreuchunas and  Mosher (1956). 
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Figure 1: Cytotoxicity of Annickia chlorantha (ACsbI) against BMDM. The toxicity was assessed 
using the MTS assay. The cells were treated for 48 h with different drug concentrations. OD was measured at 490 nm. 
Data are reported as means ± standard deviation. Significant differences were calculated by comparing results in the presence 
of cells treated or not with ACSbI at different concentrations. Calculations were performed using one way ANOVA [F (3, 
8)= 13.79 ; **, p = 0. 0016]. 
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Figure 2: Intracellular antimycobacterial effect of A. chloranta stem bark extract (ACsbI) against 
M. smegmatis infecting BMDM. Number of intracellular surviving bacteria at 0, 24 and 48 h in untreated and treated 
BMDM inoculated with 5x105 CFU was determined. Data are reported as means ± standard deviation. Significant differences 
were calculated by comparing treated and untreated cell at different time intervals. 0 h post-infection refers to 4 h after 
phagocytosis of M. smegmatis. Calculations were performed using two-way ANOVA. F (1, 12) = 569.7; ***, p <.001. 
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Table 1: List of plant species with their traditional uses and extraction yields. 
 
Plant family Species Voucher 
specimen 
number 
Traditional uses References Parts 
used  
*Solvent of 
extraction 
Extracts code **Yield 
(%) 
Leaf Methanol AMl 5.40 
Fruit Methanol AMfr 6.78 
Root Methanol AMr 3.78 
 
 
 
 
 
Zingiberaceae 
 
 
 
 
 
Aframomum 
melegueta K. 
SChum. 
 
 
 
 
 
 
43123/HNC 
Dysmenorrhea, bronco-
pulmonary disorders, sexual 
asthenia, female sterility, hay 
fever, migraines and wound 
purgative,  
Galactogogue, anthelmintic 
and haemostatic agent 
Diarrhea, smallpox, 
chickenpox, wounds, cough, 
anaemia, rheumatism, 
measles, malaria, toothache, 
cardiovascular diseases, 
diabetics and fertility control. 
Tuberculosis. Buruli ulcer 
(Tane et al., 2006; 
Adeleye et al., 
2008; Kadiri, 
2009; Ibekwe and 
Orok, 2010; 
Yemoa et al., 
2011) 
 
Stem Methanol AMst 2.55 
Ethanol ACsbMeOH 2.90 
Ethanol ACsbI 1.98 
Stem 
bark 
Ethanol ACsbH2O 0.31 
Ethanol ACstMeOH 4.60 
 
 
 
Annonaceae 
 
 
Annickia chloranta 
(Oliv.) Setten and 
Maas 
 
 
 
32065/SRF/Cam 
Jaundice and urinary tract 
infections, 
stomach malaria, 
tuberculosis, hepatitis and 
some forms of ulcer, Sore, 
fevers, vomiting, fatigue, 
Rheumatism treatment 
(Adjanohoun et 
al., 1996; Kimbi 
et al., 1996; 
Boyom 
et al., 2009; Bele 
et al., 2011; 
Tsabang et al., 
2012) 
Stem 
Ethanol ACstI 0.98 
Stem 
bark 
Ethanol AMnsbMeOH 0.31 
Twig Ethanol AMntwMeOH 0.30 
Leaf Ethanol AMnlMeOH 1.65 
Annonaceae Anonidium mannii 
Gaertm (D. Oliver) 
Engl.and Diels 
45582HNC Male infertility, complication 
of pregnancy and childbirth, 
treatment of abscess 
(Noumi et al., 
2011) 
Leaf Ethanol AMnlI 2.87 
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Twig Ethanol AMntw 
CH2CL2 
0.55 
Leaf Ethanol AnMlMeOH 4.85 
Fruit 
pulp 
Ethanol AnMppMeOH 2.32 
Seed Ethanol AnMsMeOH 3.49 
Root Ethanol AnMrMeOH 1.43 
Pericarp Ethanol AnMPMeOH 0.98 
Leaf Ethanol AnMlI 1.04 
Annonaceae Annona muricata 
Linn 
32879/ HNC Boil, cough, diarrhea, 
dermatosis, hypertension, 
rheumatism and styptic, 
worms and parasites. 
headache, fever, toothache, 
asthma. 
(Mat Salleh and 
Ahmad, 1989; 
Adewole et al., 
2009; Chan and 
Roslida , 2012) 
Twig Ethanol AnMtwMeOH 1.77 
Root Methanol CMr 12.18 
Stem Methanol CMst 10.12 
Annonaceae Chlorophytum 
macrophyllum (A. 
Rich.) Asch. 
373445/HNC Cough or cough with 
haemoptysis. 
(Adjanohoun et 
al., 1996) 
Leaf Methanol CMl 2.50 
Stem 
bark 
Ethanol MMsbMeOH 0.56 
Twig Ethanol MMtwMeOH 0.27 
Annonaceae Monodora 
myristica (Gaertn.) 
Dunal 
27690/SFR/CAM Buruli ulcer, dysentery, 
diabetes, bacterial infections, 
fevers, pain and snake bites, 
hemorrhoids, stomachache, 
and febrile pains 
(Yemoa et al., 
2011; Bele et al., 
2011; Igoli et al., 
2011) Leaf Ethanol MMlMeOH 0.65 
Annonaceae Piptostigma 
calophylium 
Mildbr. and Diels 
38333HNC Urinary tract infections Local claims Leaf Ethanol PClMeOH 1.64 
Stem 
bark 
Ethanol POsbMeOH 1.04 
Twig Ethanol POtwMeOH 0.64 
Annonaceae Polyalthia oliveri 
Engl. and Diels 
19416SRF/Cam Malaria (Boyom et al., 
2009) 
Twig Ethanol POtwI 0.37 
Stem 
bark 
Ethanol PSsbMeOH 2.04 Annonaceae Polyalthia 
suaveolens Engl. 
and Diels 
1227/SRF/CAM Malaria (Tsabang et al., 
2012) 
 Leaf Ethanol PSlMeOH 7.86 
Solanaceae Solanum 23965SRFCam Cough and pneumonia (Adjanohoun et Leaf Methanol SAl 25.44 
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Stem Methanol SAst 2.80 aculeastrum Dunal al., 1996) 
Fruit Methanol SAfr 10.57 
Methanol SJfrMeOH 12.84 
Methanol SJfr 1.1  1.43 
Methanol SJfr 2.1 0.09 
Methanol SJfr 2.2 0.46 
Methanol SJfr 2.3 1.07 
Methanol SJfr 3.1 1.00 
Methanol SJfr 3.2 1.57 
Methanol SJfr 3.3 0.95 
Methanol SJfr 3.41 0.85 
Methanol SJfr 3.42 1.09 
Methanol SJfr 3.5 0.12 
Methanol SJfr 3.6 0.072 
Methanol SJfr 4.1 0.79 
Methanol SJfr 4.2 0.23 
Methanol SJfr 4.3 0.19 
Methanol SJfr 4.4 0.05 
Anacardiaceae Sorindeia 
juglandifolia A. 
Rich. 
9176 SRFCam. Liver disease and mouth 
sores in children 
(Berhaut, 1971) Fruit 
Methanol SJfr 4.5 0.0019 
Asteraceae Spilanthes 
filicaulis 
(Schumach. and 
Thonn.) 
C.D.Adams 
11136/SFRCam Cough or cough with 
haemoptysis 
(Adjanohoun et 
al., 1996) 
Whole 
plant 
Methanol SF 8.65 
Twig Ethanol UBtwMeOH 1.30 
Leaf Ethanol UBlMeOH 0.71 
Annonaceae Uvaria baumannii 
Engl. and Diels 
6427/SRF/Cam Fatigue, abscess Local claims 
Twig Ethanol UBtwI 1.60 
Annonaceae Uvariodendron 28734/SFR/CAM Malaria Local claims Twig Ethanol UCtwI 0.50 
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callophylium R.E 
Fries 
Twig Ethanol UCtwMeOH 0.42 
Annonaceae Uvaria zenkeri 
Engl. and Diels 
57355HNC Gun-stock (Bele et al., 2011) Twig Ethanol UZtwMeOH 0.59 
Twig Ethanol UMtwMeOH 0.20 Annonaceae Uvariodendron 
molendense (Engl. 
and Diels) R.E. 
Fries 
41685 HNC Malaria Local claims 
Leaf Ethanol UMlMeOH 1.44 
Fruit Ethanol XAEfrMeOH 1.98 
Leaf Ethanol XAElMeOH 4.27 
Fruit Ethanol XAEfrH2O 0.18 
Stem Ethanol XAEstMeOH 0.10 
Annonaceae Xylopia aethiopica 
(Dunal) A Rich 
 
28725/SFR/Cam Buruli ulcer, Cough, 
carminative, and as a post-
partum tonic. 
Stomach ache, treatment of 
bronchitis, biliousness and 
dysentery 
(Iwu, 1993; 
Yemoa et al., 
2011) 
 
Leaf Ethanol XAElI 0.30 
Stem 
bark 
Ethanol XAsbH2O 0.94 
Twig Ethanol XAtwI 0.75 
Root Ethanol XArI 1.45 
Leaf Ethanol XAlMeOH 1.83 
Stem 
bark 
Ethanol XAsbI 2.02 
Root Ethanol XArH2O 0.31 
Root Ethanol XArHex 0.09 
Root Ethanol XArMeOH 0.49 
Leaf Ethanol XAlI 3.99 
Twig Ethanol XAtwMeOH 1.83 
Annonaceae Xylopia parviflora 
A Rich 
38322/HNC Bronchitis, dysentery and 
febrile pains, Asthma, 
stomach aches and 
rheumatism 
(Bele et al., 2011) 
Stem 
bark 
Ethanol XAsbMeOH 1.57 
Fruit Ethanol XPfrMeOH 1.65 
Leaf Ethanol XPlMeOH 1.96 
Annonaceae Xylopia parviflora 
A Rich 
42351HNC Stomach disorders and 
barrenness, Headache, 
analgesic and antispasmodic 
purposes 
(Nishiyama et al., 
2004) 
Stem Ethanol XPstMeOH 2.74 
*Plant materials were extracted by maceration at room temperature; **extraction yields were  
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Table 2: MIC and MBC from the antimycobacterial screening of plant extracts. 
 
MIC (µg/ml) MBC (µg/ml) Extracts code 
MS MA BCG MU MTB MS MA BCG MU MTB 
Plants fractions and purified compounds at 250 µg/ml 
ACstI 250 NA NA 7.81 NA >250 NA NA 7.81 NA 
ACsbI 250 NA 125 1.95 NA ≥250 NA >250 62.50 NA 
SJfr 3.2 NA NA 15.62 62.50 NA NA NA 62.50 ≥250 NA 
SJfr 3.3 NA NA 31.25 NA 250 NA NA 31.25 NA 250 
SJfr 3.41 NA NA NA 62.50 NA NA NA NA 250 NA 
SJfr 3.42 NA NA 31.25 NA NA NA NA 31.25 NA NA 
SJfr 3.6 NA NA 3.90 NA NA NA NA 31.25 NA NA 
SJfr 4.2 NA NA 125 NA 250 NA NA 125 NA 250 
SJfr 4.3 NA NA 250 NA NA NA NA 250 NA NA 
SJfr 4.4 NA ≥250 NA NA NA NA >250 NA NA NA 
SJfr 4.5 NA NA NA 62.50 NA NA NA NA 125 NA 
Plants crude extracts at 12,500 µg/ml 
PSsbMeOH 6,250 >12,500 12,500 3,125 6,250 12,500 >12,500 12,500 3,125 12,500 
XArH2O 12,500 NA 3,125 NA 6,250 12,500 NA 3,125 NA 12,500 
POsbMeOH 12,500 NA 6,250 NA NA ≥12,500 NA 12,500 NA NA 
AMl NA NA 12,500 NA NA NA NA 12,500 NA NA 
AMfr NA NA 6,250 NA NA NA NA 6,250 NA NA 
SF NA NA 12,500 NA NA NA NA 12,500 NA NA 
CMst NA NA 12,500 NA NA NA NA 12,500 NA NA 
CMr NA NA 3,125 NA 12,500 NA NA 6,250 NA 12,500 
AMnsbMeOH NA NA 6,250 NA 12,500 NA NA 6,250 NA 12,500 
XAsbH2O NA NA 12,500 NA NA NA NA 12,500 NA NA 
XAsbI NA NA 12,500 NA NA NA NA 12,500 NA NA 
UBtwMeOH NA NA 1,562 NA NA NA NA 3,125 NA NA 
AMntwMeOH NA NA 3,125 NA 6,250 NA NA 6,250 NA 6,250 
Positive controls (µg/ml) 
SM NT >18.00 NT 0.12 0.50 NT NT NT 0.25 0.5 
EMB 0.46 >160 1.50 NT NT >1.87 >160 >3.00 NT NT 
Abbreviations used in the table: MS: M. smegmatis; MA: M. avium; ; MU: M. ulcerans; MTB: M. tuberculosis.NA= no activity; NT= not tested; SJfr 3.6: 2,3,6-trihydroxy benzoic acid; 
SJfr 4.5: 2,3,6-trihydroxy methyl benzoate; SF: S. filicaulis; XArH2O: X. africana root water fraction CMr: C. macrophyllum root, AMntwMeOH: A. mannii twig methanolic fraction; 
PSsbMeOH: P. suaveolens stem bark; ACsbI: A. chlorantha stem bark interface; ACstI: A. chlorantha stem interface. 
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Table 3: Cytotoxicity of ACsbI, ACstI, and SJfr 3.6 against MRC5 cells. 
 
Plant fraction *IC50 ± SD (µg/ml) 
ACstI 50.82 ± 1.04 
ACsbI > 500 
SJfr 3.6 139.4 ± 1.03 
*Plant fractions were tested in triplicate; IC50 = extract concentration that inhibits  
50% of cell growth. 
 
 
DISCUSSION 
Amongst the 19 plants collected in 
this study, 9 were reported to be used to treat 
respiratory tract infections, including cough, 
bronchitis, asthma, pneumonia, TB, cough 
with haemoptysis and other broncho-
pulmonary disorders. In addition, 3 plants 
were reported as used to treat ulcers (ex. BU) 
and 7 to control other general symptoms like 
fevers, headache, and pain (Nishiyama et al., 
2004; Ibekwe and Orok, 2010).  
From the results presented (Table 2), 
extracts were more active on slow growing 
strains such as M. tuberculosis, M. ulcerans, 
and BCG than on faster growing strains such 
as M. smegmatis and M. avium. 
Overall, apart from M. avium, all the 
mycobacterial strains showed susceptibility to 
at least 1 extract. M. avium is basically 
resistant to many drugs used to treat other 
mycobacterial infections. Of note, this 
bacterial species showed low susceptibility to 
the positive controls (SM, MIC> 18 µg/ml; 
EMB, MIC > 160 µg/ml). This resistance is 
usually ascribed to the impermeability of its 
lipid-rich cell wall, but it may also occur 
through emergence of highly resistant strains, 
patient intolerance to treatment, or erratic 
compliance (Portillo-Gomez et al., 1995; 
Ramirez et al., 2007). Furthermore most M. 
avium isolates segregate into smooth-
transparent-, smooth-opaque- and rough-
colony-type variants on agar plates. M. avium 
strain 2447 is a smooth transparent (SmT) 
colony isolated from AIDS patients 
(Cangelosi et al., 2001) and for unknown 
reasons, transparent variants tend to be more 
drug-resistant than opaque variants (Florido et 
al.,1999). The low susceptibility of M. avium 
strain 2447 might also be due to the bacterial 
load used in this study. 
Two fractions from A. chlorantha 
stem and stemback (ACstI and ACsbI) 
showed activity against M. smegmatis at MIC 
value of 250 µg/ml for both and against M. 
ulcerans at MIC values of 1.95 and 7.81 
µg/ml respectively. ACstI and ACsbI showed 
bactericidal activity on M. ulcerans with MBC 
values of 7.81 and 62.50 µg /ml respectively. 
In a similar approach, previous studies were 
conducted on M. ulcerans. The MIC value 
obtained by Coulibaly et al. (2011) with an 
aqueous extract from Phyllanthus amarus was 
32 mg/ml, while results obtained by Yemoa et 
al. (2011) from the screening of 49 methanolic 
extracts from different plants showed MIC 
values ranging from 125-250 µg/ml.  
Overall, investigation of plants 
products is so far scarce for the management 
and control of BU depite the urgent need for 
effective drugs. M. ulcerans has shown high 
susceptibility to A. chlorantha stem and stem 
bark extracts (ACsbI and ACstI), S. 
juglandifolia compound (SJfr 4.5). A. 
chlorantha also known as the African yellow 
wood, is a dense forest tree found in 
Cameroon, Nigeria and Gabon where Buruli 
ulcer is endemic (WHO, 2011). In the 
southern forest zone of Cameroon, it is used 
traditionally to treat tuberculosis and some 
forms of ulcer (Adjanohoun et al., 1996; 
Kimbi et al., 1996). This plant should be 
further investigated for the treatment of BU. 
BCG appeared to be the most 
sensitive strain to much of extracts and 
fractions. Extracts from S. juglandifolia were 
found to be the most active on this strain. 
These results suggest that, the fruits of S. 
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juglandifolia should be further investigated 
for the treatment of bovine tuberculosis.  
Results from the cytotoxicity studies 
suggest a critical management of doses of 
traditional potions that are given to patients 
attending traditional herbal practitioners. 
Extract from A. chlorantha (ACsbI) was 
found to be safe at 2 fold the MIC value 
(activity against M. smegmatis). A previous 
work assessed the cytotoxicity of the water 
extract of A. chlorantha and showed to be safe 
on Vero cells up to 0.025 mg/ml (Fasola et al., 
2011), corroborating our findings. This result 
suggests that the activity of this fraction might 
be directed towards microorganisms rather 
than eukaryotic cells. The result obtained with 
ACsbI against the intracellular bacteria 
supports the local use of A. chlorantha stem 
bark in the treatment of a wide range of 
infections (Adjanohoun et al., 1996; Kimbi et 
al., 1996; Boyom et al., 2009; Bele et al., 
2011; Tsabang et al., 2012). Moreover, ACsbI 
fraction, which is obtained from an 
Annonaceae plant, might contain acetogenins 
derivatives. This group of compounds was 
reported to be the most powerful of the known 
inhibitors of complex I (NADH: ubiquinone 
oxidoreductase) in mammalian and insect 
mitochondrial electron transport systems 
(Lewis et al., 1993). In addition, they were 
shown to be potent inhibitors of NADH 
oxidase of plasma membranes (Morré et al., 
1995); leading to ATP deprivation and 
apoptosis (programmed cell death). Moreover, 
they are potently cytotoxic with bactericidal 
activities (Rupprecht et al., 1990; Guadaño et 
al., 2000; Rakotomanga et al., 2004; 
Kamkumo et al., 2012) that could explain the 
exerted antimycobacterial activity. 
 
Conclusion  
The study designed to assess the 
antimycobacterial activity of extracts from 19 
Cameroonian medicinal plants highlighted the 
potency of natural products against 4 species 
of mycobacteria, M. smegmatis, BCG, M. 
tuberculosis, and M. ulcerans. Moreover, 
ACsbI significantly inhibited the growth of 
intracellular M. smegmatis and was also 
shown not to be cytotoxic for MRC5 cell line 
and BMDM. Considering the anti-TB drug 
resistance and the increasing burden of the 
emerging BU, the results achieved are 
promising, and indicate that new drug 
candidates could be discovered through this 
approach. Of note, very few reports are 
available on investigation of plant products 
against M. ulcerans. We anticipate that further 
detailed studies within this focus will enable 
us to uncover the hidden potency of particular 
natural products from the Cameroonian 
biodiversity against TB and BU. 
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